Results 11 to 20 of about 49,999 (280)
Viabahn for femoropopliteal in-stent restenosis
Annals of Saudi Medicine, 2012 BACKGROUND AND OBJECTIVES: In-stent restenosis in the femoropopliteal artery is common (20%-40%). Treatment of in-stent restenosis is challenged by poor patency rate.
Owayed Al Shammeri +3 more
doaj +3 more sources
JACC: Basic to Translational Science, 2020 Anna Lena Lahmann, MD, Michael Joner, MD
doaj +5 more sources
Iron corroded granules inhibiting vascular smooth muscle cell proliferation
Materials Today Bio, 2022 In-stent restenosis after interventional therapy remains a severe clinical complication. Current evidence indicates that neointimal hyperplasia induced by vascular smooth muscle cell (VSMC) proliferation is a major cause of restenosis.
Dongxu Qiu +9 more
doaj +1 more source
Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model. [PDF]
, 2009 Preclinical models of restenosis are essential to unravel the pathophysiological processes that lead to in-stent restenosis and to optimize existing and future drug-eluting stents. A variety of antibodies and transgenic and knockout strains are available
Deuse, Tobias +3 more
core +2 more sources
Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. [PDF]
, 2006 Objective: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs). Design: Prospective multicentre study. Comparison with a control group.
Blindt, Ruediger +5 more
core +2 more sources
Scientific Reports, 2021 This study investigated factors affecting the safety and in-stent restenosis after intracranial stent angioplasty using the Enterprise stent for symptomatic intracranial atherosclerotic stenosis.
Kun Zhang +7 more
doaj +1 more source
Changes of Serum CTRP12 in Patients With Coronary Artery Disease After the Treatment of Percutaneous Coronary Intervention and Its Relationship With In-Stent Restenosis. [PDF]
Clin CardiolSerum CTRP12 levels are significantly lower in CAD patients, and significant correlate to disease severity and dynamic changes after PCI. They may serve as a potential biomarker for diagnosing CAD and predicting ISR occurrence. ABSTRACT Background C1q/tumor necrosis factor‐related protein 12 (CTRP12) plays a protective role in coronary artery disease ...
Zhao B, Shen Y.
europepmc +2 more sources
Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries [PDF]
, 2011 <p><b>Objective:</b> We have previously demonstrated that bindarit, a selective inhibitor of monocyte chemotactic proteins (MCPs), is effective in reducing neointimal formation in rodent models of vascular injury by reducing smooth ...
Baker, A.H. +10 more
core +1 more source
Pakistan Armed Forces Medical Journal, 2020 Objective: To study the frequency of In-Stent Restenosis and its treatment in patients undergoing Percutaneous Coronary Intervention for coronary artery disease. Study Design: Descriptive cross sectional study.
Waseem Raja +7 more
doaj +1 more source
Stent implant follow-up in intravascular optical coherence tomography images [PDF]
, 2009 The objectives of this article are (i) to utilize computer methods in detection of stent struts imaged in vivo by optical coherence tomography (OCT) during percutaneous coronary interventions (PCI); (ii) to provide measurements for the assessment ...
Carlier, Stephane Guy +4 more
core +2 more sources